As a resident, José led many clinical trials and showed the potential of targeting HER2 in breast cancer patients with HER2 overexpression and of targeting EGFR using cetuximab in EGFR-overexpressing tumors [6–8]. The gene discussed is EGFR; the disease is breast carcinoma.